You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Prolias accused PDI of breaching a joint venture agreement to validate, commercialize, and monetize Prolias' miRNA thyroid cancer test. PDI denied liability and said it would defend itself vigorously.
Cancer-ID is a newly created consortium tasked with validating blood-based biomarkers, such as CTC, cfDNA, and miRNA to bring liquid biopsies into the clinic.
In PLOS this week: GWAS links gene to noise-induced hearing loss in mice, population genetics of malaria parasites, and more.
The investment bank upgraded Rosetta's shares following the completion of the firm's purchase of PersonalizeDx earlier in the week.
With the support of an NIH grant, Nawgen aims to create assays covering all microRNAs in the human and mouse genomes.
A fourth paper from MIT's Robert Weinberg has been retracted, according to Retraction Watch.
The study indicates that miRNAs act as genomic noise dampeners, controlling variability in protein expression.
The findings build on previous work that showed a gene known to be regulated by an miRNA family influenced the growth of fruit in Arabidopsis.
The technology involves targeted sequencing of rare extracellular microRNAs ordinarily represented by low numbers of reads and therefore hard to detect.
The proof-of-principle application suggests networks of microRNA, RNA, and other 'omics data can untangle drug response and more.
The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.
Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.
A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.
In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.